NIH VideoCast - Comprehensive Molecular Profiling to Support Treatment Recommendations for Advanced Cancer

Skip Navigation

Comprehensive Molecular Profiling to Support Treatment Recommendations for Advanced Cancer

Loading... Loading video...

363 Views

Air date:	Wednesday, November 13, 2013, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 363 (98 Live, 265 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:04:27
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Wednesday Afternoon Lecture Series Prior to joining TGen, Dr. Carpten was an intramural tenure track investigator with the Cancer Genetics Branch of the National Human Genome Research Institute (NHGRI), NIH, a group that pioneered a number of innovative technologies and methods to study the underlying genetics of cancer. At NIH, he co-led the first published genome wide scan for prostate cancer susceptibility genes published in 1996 in Science. His lab subsequently discovered germ-line mutations in theRNASEL gene in HPC1-linked hereditary prostate cancer families. His contigs of the 1q24-q31 region of the human genome became the framework and template for sequencing of that 20 megabase region by the Human Genome Project. These data were also used for the subsequent discovery of two other disease genes. The PRG4 gene mapped to 1q24 and mutations within this gene result in CACP, a congenital joint disease. Also mutations in theHRPT2 gene, which maps to 1q31, were discovered in the Carpten lab and lead to hyperparathyroidism jaw-tumor syndrome. HRPT2mutation and parafibromin IHC assays are currently being developed as a clinical diagnostics for parathyroid cancer. Dr. Carpten also has an intense focus on understanding the role of biology in disparate cancer incidence and mortality rates seem among minority populations. Through his leadership, the African American Hereditary Prostate Cancer Study (AAHPC) Network was conceived. This study has become a model for genetic linkage studies in underrepresented populations and led to the first genome wide scan for prostate cancer susceptibility genes in African Americans. More recently, his group has discovered a number of single nucleotide polymorphisms, which confer increased risk of developing prostate cancer. More recently, Dr. Carpten has begun to apply Next Generation Sequencing (NGS) technologies for deep genomic profiling of tumors. These technologies offer the opportunity to sequence entire cancer genomes to discovery of mutations, copy number changes, and rearrangements such as translocations. It is his ultimate hope that his work will lead to more accurate means of cancer diagnosis and to the adoption of knowledge based therapeutic decision-making toward improving outcomes in cancer patients. For more information go to http://wals.od.nih.gov/

NLM Title:	Comprehensive molecular profiling to support treatment recommendations for advanced cancer / John Carpten.
Author:	Carpten, John. National Institutes of Health (U.S.),
Publisher:
Subjects:	Gene Expression Profiling Neoplasms--genetics Neoplasms--therapy Precision Medicine
Publication Types:	Lecture Webcast

NLM Classification:	QZ 266
NLM ID:	101622753
CIT Live ID:	13345
Permanent link:	https://videocast.nih.gov/watch=13345

Related Videos...